Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...
Pfizer (PFE) stock falls as the company posts mid-stage trial data for obesity therapy PF’3944. Read more here.
In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...
PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...
Pfizer is almost certain to survive the current headwinds as a business. However, the dividend may not. It will be important ...
Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results